Paul is a European and UK Patent Attorney. He handles all aspects of drafting, filing and prosecuting patent applications, and has particular experience in advising clients regarding freedom to operate issues and monitoring third party patent portfolios.
Paul works on cases relating to a wide range of subject matter from across the field of biotechnology. Paul has worked closely with a UK company in the field of AAV gene therapy for several years, and has developed a strong understanding of their platform technologies and their upcoming pipeline, as well as their commercial priorities and the risks posed by third parties in this field. He has advised a sequencing start-up with their international filing and prosecution strategies and helped build their patent portfolio, and was involved with their eventual sale to a large multinational corporation. Paul also has experience prosecuting cases relating to RNAi-based therapies, and more recently has been involved in opposition cases at the EPO in this area. He also has an interest in the fields of synthetic biology, rapid diagnosis assays, and the use of oligonucleotide probes for protein and nucleic acid detection.
Paul has experience in working with a range of clients, from university spinouts and start-ups to larger corporations, as well as with foreign patent firms. He particularly enjoys working with inventors to help identify potential new inventions, and advising clients on possible filing strategies.
Paul joined J A Kemp as an associate in 2019 following over five years at another leading firm of patent attorneys. He is based in J A Kemp’s London office.